Press Releases and Events

PRESS RELEASES

Press Release | February 5, 2026

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

READ MORE
Press Release | January 26, 2026

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

READ MORE
Press Release | January 22, 2026

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

READ MORE
Press Release | January 12, 2026

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | January 6, 2026

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

READ MORE
Press Release | January 5, 2026

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

READ MORE
Press Release | January 5, 2026

Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

READ MORE
Press Release | January 4, 2026

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

READ MORE
Press Release | December 18, 2025

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference

READ MORE
Press Release | December 18, 2025

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference

READ MORE
2 / 25